Increased SREBP-1c activity further drives hepatic steatosis, stimulating excessive fatty acid and triglyceride synthesis, which disrupts mitochondrial function and increases ROS production, contributing to NAFLD. This evidence concerns the gene SREBF1 and metabolic dysfunction-associated steatotic liver disease.